Editing Avacta Group Plc (section)

=== Research and development ===
The Group’s research and development activities continue to focus around the Affimer® technology within the Diagnostics Division and the Affimer® and pre|CISIONTM technologies in the Therapeutics Division. There is a risk, consistent with similar biotechnology companies developing new and innovative technology platforms, that the scientific results required for specific internal development programmes, product development projects, customer-related evaluations or third-party collaborations. This risk is in specific applications of the Affimer® or pre|CISIONTM technologies rather than in the individual technology platform as a whole. The development teams continue to work on improving the core Affimer® and pre|CISIONTM technology platforms and expanding the potential areas where the technology has significant benefits over existing antibody technologies with oversight from the Senior Management Teams, the Board and Scientific Advisory Board. With the Group’s first asset (AVA6000) progressing through clinical trials there is a risk that the trials might not be successful and that the Group is unable to develop marketable products. There is a risk that the clinical trials could lead to unanticipated results, which require further development leading to time delays. The Group has built an experienced and reputable team of clinical advisers who are monitoring the outputs of the clinical trials to ensure appropriate decisions based on data outcomes are taken at the right time.